ESR1 and breast carcinoma: Based on this scoring criteria, AM-1882 sensitivity was enriched in TP53-mutant serous ovarian cancer (55%, six of 11) and estrogen receptor (ER)-negative breast cancer (44%, seven of 16) subtypes (Supplementary Table 3).